Expression of Ephb2 and Ephb4 in Breast Carcinoma

Pathology and Oncology Research

Volumn 10, Issue 1, 2004, Pages 26-33

  Wu, Qinghua ^a   Suo, Zhenhe ^a   Risberg, Bjørn ^a   Karlsson, Mats G ^b   Villman, Kenneth ^b   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Breast carcinoma; EphB2; EphB4; Immunohistochemistry; RT PCR

Indexed keywords

CELL PROTEIN; CELL SURFACE PROTEIN; EPHRIN A1; EPHRIN RECEPTOR; EPHRIN RECEPTOR B1; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; LIGAND; PROTEIN TYROSINE KINASE;

ANEUPLOIDY; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CELL CYCLE S PHASE; CORRELATION ANALYSIS; DNA DETERMINATION; EMBRYO DEVELOPMENT; ENZYME BINDING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MEMBRANE BINDING; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; SURVIVAL;

EID: 1942536189     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893405     Document Type: Article

References (49)

1. van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Ann Rev Cell Biol 10: 251-337, 1994.
2. Gale N., Holland SJ., Valenzuela DM, et al: Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17: 9-19, 1996.
3. Davy A, Gale NW, Murray EW, et al: Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev 13: 3125-3135, 1999.
4. Davy A., Robbins SM: Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner. Embo J 19: 5396-5405, 2000.
5. Kullander K, Klein R: Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3: 475-486, 2002.
6. Flanagan JG, Vanderhaeghen P: The ephrins and Eph receptors in neural development. Ann Rev Neurosci 21: 309-345, 1998.
7. Tessier-Lavigne M: Eph receptor tyrosine kinases, axon repulsion, and the development of topographic maps. Cell 82: 345-348, 1995.
8. Wang HU, Anderson DJ: Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth. Neuron 18: 383-396, 1997.
9. Winslow JW, Moran P, Valverde J, et al: Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron 14: 973-981, 1995.
10. Chinoy MR, Graybill MM, Miller SA, et al: Angiopoietin-1 and VEGF in vascular development and angiogenesis in hypoplastic lungs. Am J Physiol Lung Cell Mol Physiol 283: L60-66, 2002.
11. Li H, Fredriksson L, Li X, et al: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 22: 1501-1510, 2003.
12. Goede V., Fleckenstein G, Dietrich M, et al: Prognostic value of angiogenesis in mammary tumors. Anticancer Res 18: 2199-2210, 1998.
13. Kuehn R, Lelkes PI, Bloechle C, et al: Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 18: 96-103, 1999.
14. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1882, 1992.
15. Zelinski DP, Zantek ND, Stewart JC, et al: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2311, 2001.
16. Miyazaki T, Kato H, Fukuchi M, et al: EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103: 657-668, 2003.
17. Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41: 275-281, 1999.
18. Ikegaki N, Tang XX, Liu XG, et al: Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. Hum Mol Genet 4: 2033-2041, 1995.
19. Nikolova Z, Djonov V, Zuercher G, et al: Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci 111: 2741-2750, 1998.
20. Cromer A, Carles A, Millon R, et al: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene (in press), 2004.
21. Kiyokawa E, Takai S, Tanaka M, et al: Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 54: 3645-3652, 1994.
22. Tang XX, Brodeur GM, Campling BG, et al: Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res 5: 455-463, 1999.
23. Tang XX, Evans AE, Zhao H, et al: High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 5: 1491-1501, 1999.
24. Tang XX, Evan, AE, Zhao H, et al: Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 36: 80-86, 2001.
25. Liu W, Ahmad SA, Jung YD, et al: Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94: 934-943, 2002.
26. Kataoka H, Tanaka M, Kanamori M, et al: Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 128: 343-352, 2002.
27. Bennett BD, Wang Z, Kuang WJ, et al: Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem 269: 14211-14220, 1994.
28. Bercla G, Karamitopoulou E, Mazzucchelli L, et al: Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 14: 220-227, 2003.
29. Stephenson SA, Slomka S, Douglas EL, et al: Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2: 15-21, 2001.
30. Berclaz G, Flutsch B, Altermatt HJ, et al: Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 9: 985-993, 2002.
31. Elston CW, Elli, IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-411, 1991.
32. Suo Z, Berner HS, Risberg B, et al: Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 439: 62-73, 2001.
33. Himanen JP, Rajashankar KR, Lackmann M, et al: Crystal structure of an Eph receptor-ephrin complex. Nature 414: 933-939, 2001.
34. Kalo MS, Pasquale EB: Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry 38: 14396-14401, 1999.
35. Dodelet VC, Pazzagli C, Zisch AH, et al: A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A. J Biol Chem 274: 31941-31946, 1999.
36. Holland SJ, Gale NW, Gish GD, et al: Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. Embo J 16: 3877-3884, 1997.
37. Ellis C, Kasmi F, Ganju P, et al: A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. Oncogene 12: 1727-1733, 1996.
38. Steinle JJ, Meininger CJ, Forough R, et al: Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 277: 43830-43836, 2002.
39. Vindis C, Cerretti DP, Daniel TO, et al: EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis. J Cell Biol 162: 661-669, 2003.
40. Stein E, Cerretti DP, Daniel TO: Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells. J Biol Chem 271: 23588-23596, 1996.
41. Stein E, Huynh-Do U, Lane AA, et al: Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem 273: 1303-1312, 1998.
42. Hock B, Bohme B, Karn T, et al: PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc Natl Acad Sci U S A 95: 9779-9785, 1998.
43. Stein E, Lane AA, Cerretti DP, et al: Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 12: 667-672, 1998.
44. Wybenga-Groot LE, Baskin B, Ong SH, et al: Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745-753, 2001.
45. Matsuzaki M, Nagase S, Abe T, et al: Detailed deletion mapping on chromosome 1p32-p36 in human colorectal cancer: identification of three distinct regions of common allelic loss. Int J Oncol 13: 1229-1238, 1998.
46. Praml C, Finke LH, Herfarth C, et al: Deletion mapping defines different regions in lp34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 11: 1357-1367, 1995.
47. Oba SM, Wang YJ, Song JP, et al: Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer. Cancer Lett 164: 97-109, 2001.
48. Adams RH: Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 13: 55-63, 2002.
49. Wang HU, Chen ZF, Anderson DJ: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741-753, 1998.